Inotek has sponsored Phase 1, Phase 2 and Phase 3 clinical trials for trabodenoson monotherapy which have concluded, as well as a Phase 2 clinical trial for trabodenoson + latanoprost in a fixed-dose combination which is currently ongoing. Click the links below to learn more about each trial through clinicaltrials.gov.
|NCT02829996||Recruiting||Fixed-dose combination||Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma|
|NCT02565173||Completed||Trabodenoson monotherapy||Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma|
|NCT01917383||Completed||Trabodenoson monotherapy||A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma|
|NCT01123785||Completed||Trabodenoson monotherapy||A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma|
|NCT01123772||Completed||Trabodenoson monotherapy||Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers|